Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners across academia, biotech, and the largest biopharma, Alloy democratizes access to pre-competitive tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics across six modalities: antibodies, TCRs, genetic medicines, cell therapies, peptides, and drug delivery. Partners may access all current and future technologies through a discovery service relationship or for a flat annual fee through Alloy’s Innovation Subscriptions offering. As a reflection of Alloy’s relentless commitment to the scientific community, Alloy reinvests 100% of its revenue in innovation and access to innovation. Alloy is headquartered in Boston, MA, with labs in Cambridge, UK; Basel, CH; San Francisco, CA; and Athens, GA. To learn how to collaborate with Alloy, connect with us at: alloytx.com/contact
Owned by Novo Holdings, Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies of all sizes a proven, flexible approach to their preclinical and clinical study needs. Headquartered in Canada, Altasciences has 9 research facilities across North America.
Altasciences’ full-service solutions include preclinical safety testing, bioanalysis, clinical pharmacology, program management, medical writing, biostatistics, and data management, all of which can be tailored to specific sponsor requirements.
Specific to preclinical research services, Altasciences' expertise spans a wide range of non-GLP and GLP CTA/IND-enabling in vivo safety assessment solutions in both rodent and non-rodent species to thoroughly evaluate pharmaceuticals, biologics, animal health products, agrochemicals, and biocides.
Our scientific and regulatory teams work with you to develop customised research programmes and to ensure that your IND/NDA-enabling toxicology, safety pharmacology, and laboratory studies comply with global regulations.
From lead candidate selection to clinical proof of concept, we offer one-stop integrated formulation, preclinical and clinical manufacturing, and analytical services.
Altasciences’ full-service solutions include preclinical safety testing, bioanalysis, clinical pharmacology, program management, medical writing, biostatistics, and data management, all of which can be tailored to specific sponsor requirements.
Specific to preclinical research services, Altasciences' expertise spans a wide range of non-GLP and GLP CTA/IND-enabling in vivo safety assessment solutions in both rodent and non-rodent species to thoroughly evaluate pharmaceuticals, biologics, animal health products, agrochemicals, and biocides.
Our scientific and regulatory teams work with you to develop customised research programmes and to ensure that your IND/NDA-enabling toxicology, safety pharmacology, and laboratory studies comply with global regulations.
From lead candidate selection to clinical proof of concept, we offer one-stop integrated formulation, preclinical and clinical manufacturing, and analytical services.
AMSBIO supplies research products and custom services to the biological and pharmaceutical industries. We sell products for routine laboratory procedures as well as more specific, cutting-edge technology. Areas of specific expertise include physiologically realistic cell culture (including 3D culture), tissues and biorepositories, Zymolyase, glycobiology, lentivirus, ELISA kits and stem cell technology. We also offer custom services in protein expression, histochemistry, peptide/antibody design and 3D culture. With offices in the UK, Germany, Switzerland and the USA, AMSBIO offers fast delivery of material. For more information, please visit https://www.amsbio.com or contact AMSBIO’s multilingual help team.
Watch our Member Showcase video here https://bit.ly/3HZMe9T
Watch our Member Showcase video here https://bit.ly/3HZMe9T
Longer form - Apollo Therapeutics is a collaborative venture between three world-leading UK universities (Imperial College London, UCL and the University of Cambridge) and three global pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Johnson & Johnson Innovation). Apollo provides committed translational funding and drug discovery expertise for novel therapeutics, sourced from the best of British academic research, accelerating them towards the clinic.. . Apollo’s unique model provides quick, independent access to the resources to grow innovations and to champion the best of British academic research to industry. Apollo’s experienced team of industry scientists have a proven track record of therapeutic delivery and work in partnership with academics and industry partners, crafting each bespoke project to optimise the chances of long-term success. Apollo Therapeutics aims to create the therapies of the future by partnering with the UK’s globally leading academic science base and UK based Pharma industry to have a real impact on patient treatments and outcomes.
Appleyard Lees is a leading intellectual property law firm with over sixty patent and trade mark attorneys and litigators.
Who we are and what we do – but also, how we do it – makes us distinctive.
We help our clients protect and monetise their intellectual property, and manage post-grant challenges, should they arise.
We offer broad sector and industry knowledge, plus the ability to adapt our services to specific client requirements, in an agile way.
With offices in UK innovation hotspots, we are positioned to give clients expert strategic IP advice in the UK and worldwide.
Who we are and what we do – but also, how we do it – makes us distinctive.
We help our clients protect and monetise their intellectual property, and manage post-grant challenges, should they arise.
We offer broad sector and industry knowledge, plus the ability to adapt our services to specific client requirements, in an agile way.
With offices in UK innovation hotspots, we are positioned to give clients expert strategic IP advice in the UK and worldwide.
No data available
Aqdot is a specialist chemical company with a focus and expertise in intelligent encapsulation technology. . . Aqdot’s proprietary technology and know-how enables valuable active products to be protected, delivered and programmed to release where and when required. This unique and disruptive platform technology has the potential to be game-changing in a wide range of industries, including household products, fragrances, personal care, agrochemicals, composites / resin curing and pharmaceuticals. . . Identifying unmet needs in these sectors, we develop products that enable our customers to introduce novel and differentiated products, reduce manufacturing costs, and make a truly positive impact on the environment.
Arecor is the world leader at improving the durability of biologic medicines. Using a rational approach to formulation design, Arecor has generated proprietary technology for stabilising therapeutic proteins, antibodies and vaccines. Arecor has partnered with the world’s largest pharmaceutical companies to enable previously impossible delivery and use options for biologics. As an example of how effective these technologies are – in over 90 per cent of the cases – Arecor’s technology can enable: solid-to-liquid re-formulations; removal of cold-chain; high-concentration delivery, e.g. 200+ mg/ml; and co-formulation of incompatible components.
Arise is an Innovation Hub for businesses specialising in the Health, Performance and Wellbeing sectors, and is part of Anglia Ruskin University (ARU). With Hubs strategically located in Chelmsford and Harlow, occupants can enjoy tailored business support, including access to grant funding, networking opportunities and serviced office facilities.
Arise is supported by the expertise and resources of ARU, providing skills, talent, innovation and business support. Arise is a partnership between ARU and Essex County Council with support from Chelmsford City Council and Harlow Council. This partnership aims to promote business growth in Essex.
Arise is supported by the expertise and resources of ARU, providing skills, talent, innovation and business support. Arise is a partnership between ARU and Essex County Council with support from Chelmsford City Council and Harlow Council. This partnership aims to promote business growth in Essex.
Artios - Experts in DDR. We are developing breakthrough cancer treatments that target DNA Damage Response (DDR) pathways to selectively kill cancer cells